Stryker (SYK) Earnings Date & Reports

Key Takeaways

• Stryker reported third quarter 2026 net sales of $6.52 billion, up 7.7% year over year, but below the analyst consensus of roughly $6.62 billion.
• Adjusted EPS (earnings per share) came in at $3.52, up 10.3% from a year ago, narrowly missing the $3.55 consensus estimate.
• Reported GAAP (Generally Accepted Accounting Principles) diluted EPS fell 11.7% to $1.96, pressured by higher expenses and special charges.
• Management lowered its full-year 2026 outlook, citing softer hip and knee procedure trends and lingering supply constraints.
• MedSurg and Neurotechnology sales grew 9.2%, while the Orthopaedics segment rose a more modest 5.7%.
• Shares slid about 7.6% in after-hours trading following the release.
• For more on Stryker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper insight into the ticker.
• Discover automated trading ideas and market signals by exploring Trending AI Robots.

Earnings Context and Why It Matters

Stryker is one of the world's largest medical technology companies, with leading positions in orthopedics, medical and surgical equipment, and neurotechnology. Its quarterly earnings serve as a key barometer for elective procedure demand, hospital capital spending, and broader healthcare utilization. The third quarter of 2026 carried added significance because the company had already navigated a cyberattack earlier in the year and a systems implementation across its orthopedics businesses. Investors were closely watching whether strong capital-equipment demand could offset softening trends in joint-replacement procedures. The results and, more importantly, the downward revision to full-year guidance provide a fresh signal on how procedure volumes and affordability pressures are shaping the medical device sector heading into 2027.

Reported Results

For the third quarter ended September 30, 2026, Stryker reported net sales of $6.52 billion, a 7.7% increase from $6.06 billion in the prior-year period. Organic sales, which exclude the effects of acquisitions and currency, also rose 7.7%. Revenue came in below the analyst consensus of approximately $6.62 billion.

Reported net earnings fell 12.3% to $753 million, with diluted EPS of $1.96, down from $2.22 a year earlier. Adjusted EPS, which strips out one-time items such as acquisition-related charges and impairments, increased 10.3% to $3.52—slightly below the $3.55 analysts had expected.

By segment, MedSurg and Neurotechnology grew 9.2%, while Orthopaedics increased 5.7%. Adjusted operating margin improved 60 basis points to 26.2%, even as reported operating margin declined to 15.9% from 18.7%. Management also cut its full-year guidance, now projecting organic sales growth of 6.5% to 7% and adjusted EPS of $14.80 to $14.90, both below prior ranges.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, breakout candidates, and market opportunities, the screener aims to make research more efficient than manual screening. For investors following Stryker's earnings trajectory, the AI Screener offers a structured way to identify comparable opportunities across the medical device space.

Market Reaction and Investor Sentiment

Investors reacted negatively to the combination of a revenue and EPS miss alongside reduced guidance. Stryker shares fell roughly 7.6% in after-hours trading, dropping to around $288. The decline reflected disappointment not only in the headline numbers but also in management's acknowledgment that hip and knee procedure markets have slowed, with CEO Kevin Lobo noting that results "fell short of our expectations." While the company's adjusted earnings growth and margin expansion demonstrated resilience, the softer demand outlook and guidance cut outweighed those positives in the eyes of the market.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether the softer hip and knee procedure environment stabilizes or deteriorates further. Management attributed the slowdown to affordability concerns tied to higher insurance premiums and deductibles, as well as increased pre-authorization denials. These factors could continue to weigh on elective joint-replacement volumes into 2027.

Supply normalization in the peripheral vascular business is another key item to track. Stryker has been restoring inventory after a supply disruption, and a full recovery is expected by year-end. Additionally, the company is working to strengthen commercial execution behind its Mako robotics platform and new product launches, areas where the earlier cyberattack and systems implementation created friction.

On the positive side, capital-equipment demand remains elevated, with a strong order book and double-digit growth in businesses such as Endoscopy and OrthoTech. Stryker also repurchased $1 billion of shares in the quarter and secured authorization for an additional $3 billion, signaling confidence in long-term value creation. Management expects solid fourth-quarter performance and momentum into 2027, but formal guidance will not arrive until early next year. Until then, procedure trends, supply recovery, and margin execution will be the primary drivers to watch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations